SILDENAFIL USE IN ANTIDEPRESSANT DRUGS INDUCED ERECTILE DYSFUNCTION da sildenafil kullanımı
Abstract
Objective: Sildenafil is a selective inhibitor of cGMP spesific phosphodiesterase type 5 which is the main isoenzyme responsible to metabolizing cyclic GMP in the penil corpus cavernosum. Sexual side effects are frequent, causing poor compliance and recently being considered effects of antidepressant treatment. In the present study, it was aimed to evaluate the efficacy of sildenafil on antidepressant induced erectile dysfunction. Method: Of twenty seven male patients who had applied to Psychiatry Department of F›rat University Medical Faculty and been started on antidepressant drugs for any indication and experienced erectile dysfunction between October-August 2000, 18 who had not contraindication and accepted to study were included to this study. Sildenafil was started at 25 mg dose and increased to 50 and 100 mg doses. Erectile dysfunction before treatment and each dose was assessed by The International Index of Erectile Function (IIEF). Results: Of the patients, 14 (77.8%) improved. The most frequent side effects were flushing (n=3) and headache (n=2). Discussion: Our results demonstrate sildenafil to be efficacious and reliable in the treatment of erectile dysfunction. Antidepresan ilaçlara bağlı erektil disfonksiyonda sildenafil kullanımıAmaç: Cinsel yan etkiler antidepresan tedavinin sık görülen, tedaviye uyumu olumsuz etkileyen ve son zamanlarda oldukça önem kazanan istenmeyen etkileridir. Sildenafil sitrat, siklik guanezin monofosfatın (cGMP) penis korpus…
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.